Literature DB >> 26662768

Low-energy spontaneous femoral fractures in patients with long-term bisphosphonate therapy.

A Zarza Pérez1, J L Martín Alguacil2, B Campos Melenchón2, A D Delgado Martínez3.   

Abstract

Long-term bisphosphonate therapy has been associated with low-energy subtrochanteric and femoral diaphyseal fractures in recent reports. We report three cases of a characteristic pathologic fracture of the subtrochanteric part of femoral, one of them bilateral.

Entities:  

Keywords:  Bisphosphonates; Femoral fractures; Osteoporosis; Subtrochanteric fractures

Year:  2011        PMID： 26662768     DOI： 10.1007/s00590-011-0905-8

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN： 1633-8065


  16 in total

1.  Atypical fractures as a potential complication of long-term bisphosphonate therapy.

Authors:  Deborah E Sellmeyer
Journal:  JAMA       Date:  2010-10-06       Impact factor: 56.272

2.  Bilateral pathologic femoral shaft fractures.

Authors:  Richard S Kane; Katherine A Hensleigh; Edith A Burns
Journal:  J Trauma       Date:  2005-02

3.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

Authors:  Brett A Lenart; Dean G Lorich; Joseph M Lane
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

4.  Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Authors:  S-K Goh; K Y Yang; J S B Koh; M K Wong; S Y Chua; D T C Chua; T S Howe
Journal:  J Bone Joint Surg Br       Date:  2007-03

Review 5.  Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.

Authors:  Andrea Giusti; Neveen A T Hamdy; Socrates E Papapoulos
Journal:  Bone       Date:  2010-05-20       Impact factor: 4.398

6.  Low-energy femoral shaft fractures associated with alendronate use.

Authors:  Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich
Journal:  J Orthop Trauma       Date:  2008 May-Jun       Impact factor: 2.512

7.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Authors:  Ernest Beng Kee Kwek; Seo Kiat Goh; Joyce Suang Bee Koh; Meng Ai Png; Tet Sen Howe
Journal:  Injury       Date:  2008-01-28       Impact factor: 2.586

8.  Giant osteoclast formation and long-term oral bisphosphonate therapy.

Authors:  Robert S Weinstein; Paula K Roberson; Stavros C Manolagas
Journal:  N Engl J Med       Date:  2009-01-01       Impact factor: 91.245

9.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

10.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.